On Thursday, Zealand Pharma has presented its report for the third quarter of the year, and in connection with this, the biotech company has downgraded its 2021 financial guidance for total product revenue.
The company is now expecting product sales of DKK 190m (USD 29.3m) with an uncertainty of 10 percent. Earlier, this estimate read DKK 220m (USD 33.9) +/- 10 percent.
According to Zealand Pharma, the downgrade comes as a result of lower-than-expected 2021 sales of the injection Zegalogue for people with severe hypoglycemia. The injection was launched in June and is Zealand Pharma's first launch managed wholly by itself during the 23 years it has existed.
Zealand Pharma also reports that the company maintains its 2021 net operating expenses guidance of DKK 1,250m (USD 192.8m) +/-10 percent.
First nine months of the year brought lower revenue
According to Thursday's report, Zealand Pharma has reached a revenue of DKK 106.4m (USD 16.4m) in the year's third quarter , which is considerably higher than last quarter's figures, where top line read DKK 56.5m (USD 8.7m).
Despite the success in Q3, year-to-date figures haven't been high enough to surpass results from the same period last year. Thus the year's first three quarters report revenue of DKK 238.6m (USD 36.8m) compared to DKK 290m (USD 44.7m) from the previous period.
In Thursday's report, it is stated that Zegalogue has reached net revenue of USD 0.5m in the period spanning July 1 to Sept. 30. Year-to-date revenue amounts to USD 0.7m.
Expenses are increasing
Looking at company costs, the third quarter has brought increasing operating expenses compared to last year. In Q3, operating expenses amounted to DKK 289.6m (USD 44.6m) up from last year's expenses of DKK 277.3m (USD 42.8m).
For the first nine months of the year, the difference is even bigger. When the first three quarters are combined, operating costs reach DKK 906.2m (USD 139.7m) versus DKK 714.5m (USD 110.2m) in the same period last year.
This is primarily due to increased sales and marketing expenses, in addition to more administrative expenses.
On the bottom line, Zealand Pharma exits the third quarter with a decifit of DKK -198.9m (USD -30.7m) compared to DKK -228.6m (USD 35.25m) the same period last year. The year-to-date deficit reads DKK -737.9 (USD -113.8m) compared to DKK -466.2m (USD -71.9m) at the end of the previous period.
Zealand Pharma enters US partnership over pump system
More from MedWatch
New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"
Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
Coloplast upgrades growth expectations following acquisition
Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.
Demant's surgical division loses president of 13 years
Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.
Hearing aid market in US grew by 37 percent in 2021
Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.
Lundbeck's migraine drug approved in EU
Vyepti has become the first approved intravenous preventative migraine treatment in the region.
Medical Director, Translational Medicine 
Health Economist 
Senior Key Account Manager 
Director Regulatory Affairs 
Design Control Specialist / System Engineer 
Director Medical Science 
Senior Associate, CMC Pharmaceutical Development 
Lead Scientist, Global STA, Royal DSM/Glycom 
Commercial Excellence Lead 
QA Manager GMP/GDP Compliance & Audits 
Senior Manager/Associate Director Regulatory Affairs 
Chemists are wanted for ALK's internal Aircraft Corps 
NORDIC Medical Sales Director 
GxP QA Compliance Manager for Quality Assurance